These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27391631)

  • 1. Rituximab Use in Pediatric Dermatology.
    Hoffman MB; Bhandari RA; Sinha AA
    J Drugs Dermatol; 2016 Jul; 15(7):821-9. PubMed ID: 27391631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Success of anti-CD20 monoclonal antibody treatment for severe autoimmune hemolytic anemia caused by warm-reactive immunoglobulin A, immunoglobulin G, and immunoglobulin M autoantibodies in a child: a case report.
    Ajmi H; Mabrouk S; Hassayoun S; Regaieg H; Tfifha M; Jalel C; Skouri H; Zouari N; Abroug S
    J Med Case Rep; 2017 Nov; 11(1):321. PubMed ID: 29132419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a B-cell depletion therapy for dermatologic disease.
    Prajapati V; Mydlarski PR
    Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: applications in dermatology.
    Fatourechi MM; el-Azhary RA; Gibson LE
    Int J Dermatol; 2006 Oct; 45(10):1143-55; quiz 1155. PubMed ID: 17040427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Synergy, Neutrality, and Antagonism: Combination Treatment in Dermatology.
    Strom MA; Mohan GC; Lio PA
    J Drugs Dermatol; 2016 Oct; 15(10):1203-1207. PubMed ID: 27741337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Use of Rituximab and Intravenous Immunoglobulin for Severe Autoimmune Cicatricial Conjunctivitis-An Interventional Case Series.
    Steger B; Madhusudan S; Kaye SB; Stylianides A; Romano V; Maqsood SE; Harper J; Ahmad S
    Cornea; 2016 Dec; 35(12):1611-1614. PubMed ID: 27661067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
    Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
    Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab: Uses in Dermatology.
    Gleghorn K; Wilson J; Wilkerson M
    Skin Therapy Lett; 2016 Sep; 21(5):5-7. PubMed ID: 27603326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovations in Pediatric Dermatology.
    Weinstein M; Kamat D
    Pediatr Ann; 2016 Aug; 45(8):e278-9. PubMed ID: 27517354
    [No Abstract]   [Full Text] [Related]  

  • 10. Beyond Psoriasis: Novel Uses for Biologic Response Modifiers in Pediatric Dermatology.
    Bellodi-Schmidt F; Shah KN
    Pediatr Dermatol; 2016; 33(1):18-27. PubMed ID: 26607958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in dermatology.
    España A; Ornilla E; Panizo C
    Actas Dermosifiliogr; 2013 Jun; 104(5):380-92. PubMed ID: 23665436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label uses of rituximab in dermatology.
    Carr DR; Heffernan MP
    Dermatol Ther; 2007; 20(4):277-87. PubMed ID: 17970893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.
    Pranzatelli MR; Tate ED; McGee NR; MacArthur CA
    Pediatr Neurol; 2018 Aug; 85():71-75. PubMed ID: 30197220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
    Foster CS; Chang PY; Ahmed AR
    Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE; Nunley K; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Obinutuzumab in Children With Autoimmune Encephalitis and Early B-Cell Repopulation on Rituximab.
    Nguyen AT; Cotteret C; Gins C; Sarda E; Durrleman C; Mesples B; Bustamante J; Fayard C; Cisternino S; Desguerre I; Aubart M
    Pediatr Neurol; 2024 Jul; 156():79-84. PubMed ID: 38733858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
    Fluge Ø; Risa K; Lunde S; Alme K; Rekeland IG; Sapkota D; Kristoffersen EK; Sørland K; Bruland O; Dahl O; Mella O
    PLoS One; 2015; 10(7):e0129898. PubMed ID: 26132314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics in dermatology: adverse effects.
    Sehgal VN; Pandhi D; Khurana A
    Int J Dermatol; 2015 Dec; 54(12):1442-60. PubMed ID: 26147909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GP2013: A Rituximab Biosimilar.
    Blair HA
    BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.